Publications by authors named "Samuel Anyanwu"

Claim this Profile
E
Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's Disease.
Marla C Dubinsky, Geert D'Haens, Olivier Dewit, Pascal Juillerat, Remo Panaccione, Samuel I Anyanwu

Inflamm Bowel Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE Long-Term Extension study.
Edward V Loftus, Geert D'Haens, Edouard Louis, Miguel Regueiro, Vipul Jairath, Samuel I Anyanwu

J Crohns Colitis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study.
Remo Panaccione, Miguel Regueiro, Scott D Lee, Raja Atreya, Gitte Pedersen, Samuel I Anyanwu

Clin Gastroenterol Hepatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials.
Jean-Frédéric Colombel, Ana P Lacerda, Peter M Irving, Remo Panaccione, Walter Reinisch, Samuel I Anyanwu

Clin Gastroenterol Hepatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.
Laurent Peyrin-Biroulet, Remo Panaccione, Edouard Louis, Raja Atreya, David T Rubin, Samuel I Anyanwu

Clin Gastroenterol Hepatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.
Jean-Frédéric Colombel, Tadakazu Hisamatsu, Raja Atreya, Francesca Bresso, Lena Thin, Samuel I Anyanwu

Clin Gastroenterol Hepatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Treatment and Care Patterns in Patients With Rheumatoid Arthritis Initiating First-Line Tumor Necrosis Factor Inhibitor Therapy in the United States.
Colin Edgerton, Andrew Frick, Simon Helfgott, Kent Kwas Huston, Jasvinder A Singh, Samuel I Anyanwu

ACR Open Rheumatol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.
Andrea Rubbert-Roth, Adriana M Kakehasi, Tsutomu Takeuchi, Marc Schmalzing, Hannah Palac, Samuel I Anyanwu

Rheumatol Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of HIV-1 and Human Proteins in Urinary Extracellular Vesicles from HIV+ Patients.
Samuel I Anyanwu, Akins Doherty, Michael D Powell, Chamberlain Obialo, Ming B Huang

Adv Virol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No evidence for association of autism with rare heterozygous point mutations in Contactin-Associated Protein-Like 2 (CNTNAP2), or in Other Contactin-Associated Proteins or Contactins.
John D Murdoch, Abha R Gupta, Stephan J Sanders, Michael F Walker, John Keaney, Samuel Anyanwu

PLoS Genet· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi.
Eva Sapi, Navroop Kaur, Samuel Anyanwu, David F Luecke, Akshita Datar

Infect Drug Resist· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis